The Effect of The Number of Potential Drug-Drug Interactions and Prescribed Medications on Length of Stay and Mortality Rate of Patients in The Intensive Care Unit Drug-Drug Interactions and ICU Outcome
International Pharmacy Acta,
Vol. 4 No. 1 (2021),
Introduction: The incidence rate of potential drug-drug interaction (PDDIs) in medical prescriptions was reported from 5.4% to 63% depending on the studied population, duration of the study, and different methods used to classify this. The importance of DDIs is in terms of their impact on clinical outcome. The main aim of this retrospective study was the evaluation of the impact of DDIs on ICU outcome i.e. ICU Length of stay (ICULS) and mortality.
Methods and Results: The prescribed medications of 262 patients older than 18 years with ICULS more than 48 hours admitted to the ICU during 8 months were evaluated for the risk of PDDIs. We detected a significantly increased ICULS (from 7.03 ± 5.49 days to 19.14 ± 17.64 days, p=0.035) and mortality rate (OR, 3.76; 95% CI 1.47-9.62; p=0.006) in patients with at least one D or X interaction compared to those without them. The frequency of these interactions was 73.6%. We also observed a significant association between the number of prescribed medications (r=0.79, p=0.001) and PDDIs (r=0.86, p=0.001) with increased ICULS.
Conclusion: According to the high prevalence of PDDI among ICU patients due to their large number of prescribed medications, long time of treatment, and complicated diseases, and its significant positive correlation with ICULS and mortality, it is recommended monitoring the medications of patients who received more than 5 drugs for interactions to increase the chance of prevention of significant PDDIs and decrease LOS, costs, and mortality.
- Drug-Drug Interactions, Length of Stay, Mortality, Prescribed Medications, Outcome
How to Cite
2.Heininger-Rothbucher D, Bischinger S, Ulmer H, Pechlaner C, Speer G, Wiedermann CJ. Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation. 2001;49:283-8.
3.Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. Journal of clinical pharmacy and therapeutics. 2005;30:13-20.
4.Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2006;9:427-33.
5.Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients--frequent but mostly clinically insignificant. European journal of clinical pharmacology. 2005;61:675-81.
6.Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, Krzyzanowska MK. Potential drug interactions in cancer patients receiving supportive care exclusively. Journal of pain and symptom management. 2008;35:535-43.
7.Haji Aghajani M, Sistanizad M, Abbasinazari M, Abiar Ghamsari M, Ayazkhoo L, Safi O, Kazemi K, et al. Potential Drug-drug Interactions in Post-CCU of a Teaching Hospital. Iranian journal of pharmaceutical research : IJPR. 2013;12:243-8.
8.Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2009;12:266-72.
9.Hammes JA, Pfuetzenreiter F, Silveira F, Koenig A, Westphal GA. Potential drug interactions prevalence in intensive care units. Revista Brasileira de terapia intensiva. 2008;20:349-54.
10.Moura C, Prado N, Acurcio F. Potential drug-drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study. Clinical drug investigation. 2011;31:309-16.
11.Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo, Brazil). 2011;66:9-15.
12.Rodrigues AT, Stahlschmidt R, Granja S, Falcao AL, Moriel P, Mazzola PG. Clinical relevancy and risks of potential drug-drug interactions in intensive therapy. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. 2015;23:366-70.
- Abstract Viewed: 206 times
- PDF Downloaded: 98 times